Is HIMS Stock a Buy After the Earnings Selloff? What the Full-Year Guidance Raise Actually Implies

HIMS stock just delivered one of those confusing setups that catches investors off guard. HIMS stock sold off after earnings. HIMS stock also came with a raised full-year outlook. That looks contradictory at first, but the split reaction makes sense once you separate business momentum from regulatory risk. The core platform is still growing fast, with higher revenue guidance, more subscribers, and strong near-term sales momentum. The problem is that the market is not pricing Hims & Hers on growth alone. It is also pricing the uncertainty around compounded GLP-1 drugs, and that changes the buy decision at current levels.

The Bottom Line

• Q2 2026 showed strong operating momentum: revenue rose 38% year over year to about $753 million, and subscribers reached nearly 2.9 million.
• Management raised 2026 revenue guidance to $3.1 billion to $3.3 billion, with adjusted EBITDA guidance of $275 million to $325 million.
• The selloff appears tied less to the quarter itself and more to unresolved GLP-1 regulatory and legal risk.
• For investors, HIMS stock is not a simple yes or no. The answer depends on your time horizon and your tolerance for regulatory volatility.

What HIMS's Guidance Raise Actually Showed About the Business

The headline from the quarter was simple: the business kept expanding. According to Hims & Hers investor relations, Q2 2026 revenue reached approximately $753.2 million, up 38% from a year earlier. Subscribers grew nearly 19% year over year to almost 2.9 million. Management then raised full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion.

That matters because raised guidance usually tells you management sees enough demand visibility to commit publicly to a stronger outlook. This was not just a quarter boosted by one-time momentum. It suggested the platform is still scaling across categories and still converting users into recurring subscription relationships, which remains the real engine behind the HIMS stock story.

At the same time, investors should not pretend every line in the report improved. Nasdaq’s earnings release summary showed Q2 gross margin fell to 64% from 76% a year earlier, and net income swung to a net loss of $86.3 million from prior-year net income. So the takeaway is not that Hims suddenly became a perfectly clean growth story. The real message is that demand remains strong, but profitability and product mix are moving through a more volatile phase.

Why Raising Guidance Produced a Selloff Rather Than a Rally

When a stock falls after raised guidance, the market is usually telling you it cares more about the durability of future earnings than the quality of the last quarter. That seems to be the case here.

For HIMS stock, investors are asking a harder question than “Was this quarter good?” They are asking whether the current growth rate can be trusted if the regulatory backdrop changes. If a large part of investor excitement has been tied to weight-loss demand, then uncertainty around how that business can legally continue creates a discount on the whole stock.

This is why the post-earnings price reaction should not automatically be read as a rejection of the business itself. It looks more like a market that does not want to pay a premium multiple while a major revenue driver remains exposed to headline risk, legal pressure, and possible rule changes. In other words, the selloff reflects a lower confidence in forecasting, not necessarily a collapse in demand.

What the FDA's GLP-1 Shortage Declaration Actually Is and Why It Matters

This is the key point many newer investors miss. The FDA shortage framework is not a small technical detail. It is the legal basis that has allowed compounders to make versions of drugs like semaglutide when branded supply is deemed insufficient.

If that shortage condition no longer applies, the ability to keep offering compounded versions can narrow sharply or stop, depending on the product and facts involved. That is why this is not a normal competitive risk. A normal competitive risk means another company takes market share. A regulatory survival risk means the business model itself may have to change.

Industry coverage from Pharmacy Times noted that regulatory pressure around compounded GLP-1s escalated in 2026, including legal action by Novo Nordisk in February over compounded semaglutide and related promotional claims. Other reporting cited broader FDA warning activity toward telehealth firms marketing compounded GLP-1 products. Some reports also mention additional enforcement-related developments, though parts of that remain subject to further official confirmation.

For HIMS stock, that means investors are not just tracking product demand. They are tracking whether the rules that made part of that demand monetizable stay in place.

What HIMS's Business Looks Like Without GLP-1 Revenue

This is where the bull case still has substance. Hims & Hers did not appear out of nowhere because of GLP-1. Before the weight-loss wave, the company had already built a large direct-to-consumer telehealth and subscription business across sexual health, hair loss, dermatology, mental health, and other recurring care categories.

Those businesses matter because they are more established, easier for investors to model, and less dependent on the shortage-related compounding framework. They also fit the company’s broader platform model: acquire users efficiently, keep them in recurring plans, and expand wallet share over time. In a different sector, crypto investors would call this the base-layer utility of the network. The flashy narrative can change, but the underlying user engine is what supports long-term value.

That does not mean the non-GLP-1 business alone deserves any valuation investors want to assign. It means there is a floor to the HIMS stock thesis that exists even if the market eventually strips out some of the current GLP-1 optimism. The more confidence investors have in the durability of the legacy subscription categories, the easier it becomes to view the recent pullback as an opportunity instead of a warning sign.

The Federal Reserve Rate Cut Signal That Benefits HIMS Indirectly

Hims & Hers is not a rate-sensitive bank or a DeFi lending protocol, but monetary policy still matters. If the Federal Reserve shifts toward lower rates, growth stocks often benefit because future cash flows become more valuable in present terms. Companies that are still scaling can also get more room from the market when financing conditions ease and risk appetite improves.

That support is indirect, not fundamental. Lower rates will not solve FDA risk. They will not settle legal disputes. But they can help market sentiment toward companies with strong revenue growth and expanding market share, especially when investors rotate back into higher-beta names. Yahoo Finance data shows HIMS has had a volatile trading profile, with a wide 52-week range and a beta above 2, which tells you macro sentiment can amplify the move in either direction.

The Three Investor Profiles and Their Different Answers at Current Prices

The buy decision on HIMS stock depends heavily on who you are.

Long-term investors

If you think in multi-year terms, the case is reasonably constructive. The company still has a large and growing subscriber base, a recognizable brand, and multiple recurring care categories that are not built around one regulatory loophole. For this group, current levels can be attractive if you accept that volatility may stay high and the path will not be smooth.

Six-to-twelve-month investors

This group has the hardest choice. The business momentum is real, but the visibility is not clean enough. If your holding period is under a year, waiting for better clarity around GLP-1 regulation may be the more disciplined move. You may miss the first bounce, but you also reduce the chance of getting trapped by a negative regulatory headline.

Short-term traders

For traders, HIMS stock remains a volatility vehicle. The same way crypto traders watch liquidity, narrative shifts, and headline sensitivity around a token’s ecosystem, equity traders should treat HIMS as a news-driven setup. Earnings strength can matter less than one regulatory development. That can create opportunity, but it also raises risk sharply.

What the November Earnings Report Needs to Show for the Buy Case to Hold

The next report does not need to remove every uncertainty, but it does need to do three things. First, the company needs to show that subscriber growth and broader platform demand remain healthy outside the GLP-1 narrative. Second, investors will want evidence that margin pressure is stabilizing, even if gross margin does not immediately return to earlier levels. Third, management needs to communicate clearly about compliance, product strategy, and how exposed future growth is to any single regulatory pathway.

If November shows the core business is still compounding while the company becomes more credible on risk management, the recent selloff may look overdone. If instead the update raises more questions about durability, the market will likely keep treating HIMS stock as a discounted growth story rather than a premium one.

Right now, the cleanest answer is conditional: HIMS stock can be a buy after the earnings selloff, but only if you believe the company’s non-GLP-1 platform is strong enough to carry the valuation while the regulatory dust settles. That is a reasonable stance for patient investors. It is a much weaker setup for anyone who needs certainty in the next few quarters.